ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Read More…
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees13,670
Next Earnings Date2/19/2020 (Confirmed)
OptionableOptionable
Icon (NASDAQ:ICLR) Frequently Asked Questions
What is Icon's stock symbol?
Icon trades on the NASDAQ under the ticker symbol "ICLR."
How were Icon's earnings last quarter?
Icon Plc (NASDAQ:ICLR) issued its earnings results on Wednesday, October, 23rd. The medical research company reported $1.74 earnings per share for the quarter, hitting the Zacks' consensus estimate of $1.74. The medical research company earned $710.40 million during the quarter, compared to analysts' expectations of $709.75 million. Icon's quarterly revenue was up 8.5% compared to the same quarter last year. During the same period last year, the firm posted $1.54 EPS. View Icon's Earnings History.
When is Icon's next earnings date?
How can I listen to Icon's earnings call?
Icon will be holding an earnings conference call on Wednesday, February 19th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Icon issued on next quarter's earnings?
Icon issued an update on its FY20 earnings guidance on Tuesday, January, 14th. The company provided EPS guidance of $7.55-7.85 for the period, compared to the Thomson Reuters consensus estimate of $7.71. The company issued revenue guidance of $2.97-3.09 billion, compared to the consensus revenue estimate of $3.03 billion.
What price target have analysts set for ICLR?
9 analysts have issued 1 year target prices for Icon's shares. Their forecasts range from $154.00 to $185.00. On average, they anticipate Icon's share price to reach $169.50 in the next year. This suggests that the stock has a possible downside of 3.3%. View Analyst Price Targets for Icon.
What is the consensus analysts' recommendation for Icon?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Icon.
Has Icon been receiving favorable news coverage?
Press coverage about ICLR stock has trended somewhat positive recently, InfoTrie reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Icon earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Icon.
Are investors shorting Icon?
Icon saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 1,180,000 shares, an increase of 16.8% from the December 31st total of 1,010,000 shares. Based on an average daily trading volume, of 254,500 shares, the days-to-cover ratio is presently 4.6 days. Currently, 2.2% of the company's shares are sold short. View Icon's Current Options Chain.
What other stocks do shareholders of Icon own?
Who are Icon's key executives?
Icon's management team includes the folowing people:
- Dr. Steven A. Cutler, CEO & Director (Age 59)
- Mr. Brendan Brennan, Chief Financial Officer (Age 40)
- Jonathan Curtain, VP of Corp. Fin. & Investor Relations
- Mr. Thomas O'Leary, Chief Information Officer
- Mr. Diarmaid Cunningham, Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec. (Age 44)
Who are Icon's major shareholders?
Icon's stock is owned by many different of institutional and retail investors. Top institutional investors include WCM Investment Management LLC (6.75%), Renaissance Technologies LLC (4.35%), Acadian Asset Management LLC (3.91%), Earnest Partners LLC (3.80%), Comgest Global Investors S.A.S. (3.26%) and Massachusetts Financial Services Co. MA (2.95%).
Which institutional investors are selling Icon stock?
ICLR stock was sold by a variety of institutional investors in the last quarter, including Pendal Group Ltd, Bank of New York Mellon Corp, Lord Abbett & CO. LLC, FMR LLC, PNC Financial Services Group Inc., Principal Financial Group Inc., Partner Fund Management L.P. and Legato Capital Management LLC.
Which institutional investors are buying Icon stock?
ICLR stock was bought by a variety of institutional investors in the last quarter, including Investec Asset Management LTD, Comgest Global Investors S.A.S., Massachusetts Financial Services Co. MA, FIL Ltd, WCM Investment Management LLC, Knights of Columbus Asset Advisors LLC, Polen Capital Management LLC and Renaissance Technologies LLC.
How do I buy shares of Icon?
Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Icon's stock price today?
One share of ICLR stock can currently be purchased for approximately $175.28.
MarketBeat Community Rating for Icon (NASDAQ ICLR)
MarketBeat's community ratings are surveys of what our community members think about Icon and other stocks. Vote "Outperform" if you believe ICLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICLR will underperform the S&P 500 over the long term. You may vote once every thirty days.
